Transcranial Puls Stimulation (TPS) has demonstrated high tolerability and early signs of therapeutic stability in clinical practice. This non-invasive procedure is becoming increasingly established in neurological care.
17,690 Sessions Without Relevant Side Effects
A comprehensive study conducted across 33 specialized centers evaluated data from 785 Alzheimer’s patients in 2025. In over 17,690 treatments, no clinically relevant side effects were reported. Only a few patients mentioned mild, transient headaches. This analysis suggests that the condition of the treated patients did not progress further during the observation period.
By mid-2026, approximately 290,000 TPS sessions have been performed worldwide. The procedure utilizes short sound pulses that penetrate up to eight centimeters into the brain. Since 2018, it has had CE certification for Alzheimer’s treatment. The standard protocol involves six initial treatments over two weeks, followed by regular refreshers. There is no need to shave the scalp, as the pulses are transmitted painlessly via a coupling system.
Research Expanding: From Long COVID to ADHD
The scientific investigation of TPS is gaining international traction. The University of Hong Kong is conducting the largest study to date, with 180 participants, comparing the method for attention disorders with neurofeedback. Simultaneously, the Medical University of Vienna is examining the effectiveness of TPS in treating Long COVID in a randomized, double-blind study involving 102 patients.
Despite the advancement in medications, Alzheimer’s often continues to progress. For those exploring alternatives, TPS provides a promising, non-invasive option with over 17,690 sessions yielding no relevant side effects. A free knowledge check is available to determine if this therapy is suitable for your loved one. It is not a medical test or diagnosis. Request Knowledge Check via Email
Over 250 clinics and practices worldwide offer TPS therapy—more than 100 of them located in Germany, Austria, and Switzerland. Clinical trials are also evaluating its use in treating Parkinson’s disease, depression, and ADHD. Alzheimer’s progress is being documented through a register at Heinrich Heine University Düsseldorf that tracks treatment outcomes over time.
New Antibodies—An Alternative Approach
Starting June 2026, the first antibody therapies—Lecanemab and Donanemab—are now available in Germany, potentially suitable for about 120,000 of the nation’s 1.2 million affected individuals. These medications aim to remove amyloid deposits but carry risks such as brain swelling or bleeding. In contrast, physical methods like TPS focus on activating the body’s own regenerative processes.
Does this concern you? Approximately 1.84 million people in Germany are affected by dementia. A free risk checklist will help you understand treatment options and find TPS centers near you. Request Risk Checklist
Progress has also been made in diagnostics: certified blood tests based on the p-Tau217 marker are now available in Bremen, identifying Alzheimer’s years before the first symptoms emerge. A study published in July 2026 also suggests that diabetes medications such as SGLT2 inhibitors and GLP-1 agonists may reduce the risk of dementia.
Given that around 1.84 million individuals suffer from dementia in Germany alone, experts advocate for a multimodal approach—early diagnosis, preventive measures, and combined therapeutic forms.
